Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
Michael S. Lee, Baek‐Yeol Ryoo, Chih‐Hung Hsu, et al.
The Lancet Oncology (2020) Vol. 21, Iss. 6, pp. 808-820
Closed Access | Times Cited: 473

Showing 1-25 of 473 citing articles:

Immunotherapies for hepatocellular carcinoma
Josep M. Llovet, Florian Castet, Mathias Heikenwälder, et al.
Nature Reviews Clinical Oncology (2021) Vol. 19, Iss. 3, pp. 151-172
Closed Access | Times Cited: 1159
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
Deborah Blythe Doroshow, Sheena Bhalla, Mary Beth Beasley, et al.
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 6, pp. 345-362
Closed Access | Times Cited: 1046
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
Ann‐Lii Cheng, Shukui Qin, Masafumi Ikeda, et al.
Journal of Hepatology (2021) Vol. 76, Iss. 4, pp. 862-873
Open Access | Times Cited: 1000
Targeted therapy for hepatocellular carcinoma
Ao Huang, Xin‐Rong Yang, Wen Yuan Chung, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 536
Evolving therapeutic landscape of advanced hepatocellular carcinoma
Chen Yang, Hailin Zhang, Linmeng Zhang, et al.
Nature Reviews Gastroenterology & Hepatology (2022) Vol. 20, Iss. 4, pp. 203-222
Closed Access | Times Cited: 422
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial
Robin Kate Kelley, Lorenza Rimassa, Ann‐Lii Cheng, et al.
The Lancet Oncology (2022) Vol. 23, Iss. 8, pp. 995-1008
Open Access | Times Cited: 386
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma
Andrew X. Zhu, Alexander R. Abbas, Marina Ruiz de Galarreta, et al.
Nature Medicine (2022) Vol. 28, Iss. 8, pp. 1599-1611
Closed Access | Times Cited: 355
YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis
Ruize Gao, Ravi Kiran Reddy Kalathur, Mairene Coto‐Llerena, et al.
EMBO Molecular Medicine (2021) Vol. 13, Iss. 12
Open Access | Times Cited: 352
Management of Hepatocellular Carcinoma
Zachary J. Brown, Diamantis I. Tsilimigras, Samantha M. Ruff, et al.
JAMA Surgery (2023) Vol. 158, Iss. 4, pp. 410-410
Closed Access | Times Cited: 324
The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
Tang Qing, Yun Chen, Xiaojuan Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 275
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
Adel Naimi, Rebar N. Mohammed, Ahmed Raji, et al.
Cell Communication and Signaling (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 273
Molecular pathogenesis and systemic therapies for hepatocellular carcinoma
Josep M. Llovet, Roser Pinyol, Robin Kate Kelley, et al.
Nature Cancer (2022) Vol. 3, Iss. 4, pp. 386-401
Open Access | Times Cited: 273
Emerging Therapies for Hepatocellular Carcinoma (HCC)
Eesha Chakraborty, Devanand Sarkar
Cancers (2022) Vol. 14, Iss. 11, pp. 2798-2798
Open Access | Times Cited: 206
Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities
Stephen P. Hack, Andrew X. Zhu, Yulei Wang
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 201
Angiogenesis as a hallmark of solid tumors - clinical perspectives
Jamal Majidpoor, Keywan Mortezaee
Cellular Oncology (2021) Vol. 44, Iss. 4, pp. 715-737
Closed Access | Times Cited: 186
Combination immunotherapy for hepatocellular carcinoma
Lorenza Rimassa, Richard S. Finn, Bruno Sangro
Journal of Hepatology (2023) Vol. 79, Iss. 2, pp. 506-515
Open Access | Times Cited: 166
Tumor angiogenesis: Current challenges and therapeutic opportunities
Fares Hezam Al-Ostoot, Salma Salah, Hussien Ahmed Khamees, et al.
Cancer Treatment and Research Communications (2021) Vol. 28, pp. 100422-100422
Open Access | Times Cited: 164
Recent advances in systemic therapy for hepatocellular carcinoma
Huajun Zhang, Wuyang Zhang, Longying Jiang, et al.
Biomarker Research (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 162
Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma
Chang Gon Kim, Chan Kim, Sang Eun Yoon, et al.
Journal of Hepatology (2020) Vol. 74, Iss. 2, pp. 350-359
Closed Access | Times Cited: 151
Regulatory mechanisms of PD-1/PD-L1 in cancers
Xin Lin, Kuan Kang, Pan Chen, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 100
New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects
Maohua Huang, Yuning Lin, Chenran Wang, et al.
Drug Resistance Updates (2022) Vol. 64, pp. 100849-100849
Closed Access | Times Cited: 96
The Research Progress of Antiangiogenic Therapy, Immune Therapy and Tumor Microenvironment
Haoyue Hu, Yue Chen, Songtao Tan, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 89
Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma
Andrew X. Zhu, Farshid Dayyani, Chia‐Jui Yen, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 16, pp. 3537-3545
Open Access | Times Cited: 85
Reassessing vascular endothelial growth factor (VEGF) in anti-angiogenic cancer therapy
Tobiloba Elebiyo, Damilare Rotimi, Ikponmwosa Owen Evbuomwan, et al.
Cancer Treatment and Research Communications (2022) Vol. 32, pp. 100620-100620
Open Access | Times Cited: 85
Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma
Deniz Tümen, Philipp Heumann, Karsten Gülow, et al.
Biomedicines (2022) Vol. 10, Iss. 12, pp. 3202-3202
Open Access | Times Cited: 81
Page 1 - Next Page

Scroll to top